Citigroup Downgrades Mednax to Neutral, Announces $29 Price Target

Citigroup analyst Ralph Giacobbe downgrades Mednax (NYSE:MD) from Buy to Neutral and announces $29 price target.

Benzinga · 01/03/2020 11:50

Citigroup analyst Ralph Giacobbe downgrades Mednax (NYSE:MD) from Buy to Neutral and announces $29 price target.